Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
242478-38-2O=C(O)CCC(=O)O.O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1RXZMMZZRUPYENV-VROPFNGYSA-NSolifenacin succinate is a member of isoquinolines.
242478-38-2DTXSID30947075CHEMBL1200803CHEBI:32151Breast Feeding; Lactation; Muscarinic Antagonists; Parasympatholytics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (92.8%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 69 reports by companies from 12 notifications to the ECHA C&L Inventory.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Solifenacin succinate
vLess-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
SOLIFENACIN SUCCIATE
Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]
SOLIFENACIN SUCCINATE
Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]
SOLIFENACIN SUCCINATE TABLETS
Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.
VerwendenSolifenacin succinate is a urinary antispasmodic of the antimuscarinic class.